H.C. Wainwright analyst Robert Burns lowered the firm’s price target on BioNTech to $210 from $272 and keeps a Buy rating on the shares. The analyst believes long-term COVID-19 vaccine utilization rates will continue to trend lower, and be partially counterbalanced by higher pricing.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BNTX:
- FDA moving towards authorizing second omicron booster, WSJ reports
- BioNTech, OncoC4 enter collaboration to develop, commercialize ONC-392
- BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
- BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
- BioNTech announces establishment of interdisciplinary mRNA excellence center
